3.00% of the stock is owned by insiders. A number of large investors have recently bought and sold shares of TELL. BNP Paribas Financial Markets grew its stake in Tellurian by 22.9% in the 1st ...

Vanguard Group Inc. grew its stake in shares of Tellurian by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 37,380,931 shares of the oil and gas producer’s stock valued at $24,724,000 ...

Woodside Energy Group Ltd has completed the acquisition of Tellurian Inc., purchasing all issued and outstanding common stock for roughly $900 million, or $1.00 per share, resulting in an implied ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Currently, the company's market capitalization stands at approximately $892.985 million, with a recent stock price of $0.999, reflecting a year-to-date increase of 33.75%. Tellurian's financial ...

for the stock portion. The enterprise value of approximately $1.2 billion “includes s $50 million for Tellurian’s Series C Convertible Preferred equity shares, ~$65 million of net debt ...

Tokyo Gas in talks with Woodside Energy for a stake in Louisiana LNG project, part of strategy to secure U.S. gas supply.

In other recent news, Tellurian Inc. has updated its certificate of incorporation to include details of its Series C Convertible Preferred Stock, a move that rectifies a previous omission. The ...

In other developments, Tellurian has corrected an omission in its certificate of incorporation to include details of its Series C Convertible Preferred Stock. This administrative adjustment does not ...

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% ...

Tellurian shares jumped 16.3% to $0.6050 in ... TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 ...

Woodside has acquired all issued and outstanding Tellurian common stock for approximately $900 million cash, or $1.00 per share. The implied enterprise value is approximately $1,200 million.1 Woodside ...